

[Poster 338]: Tanruprubart Improves Health-Related Quality of Life in Patients With Guillain-Barré Syndrome Compared to Placebo

Glenn Morrison, MSc, PhD


VP, Clinical Development

Annexon Biosciences

Tanruprubart (ANX005) is investigational and has not been approved for any indication in any jurisdiction. This study was funded by Annexon Biosciences (Brisbane, CA, USA). Medical writing and editing assistance were provided by Envision Pharma Group and were funded by Annexon Biosciences. Glenn Morrison is employed by and owns equity in Annexon Biosciences.

Rationale

- GBS is a rare, rapidly progressive, life-threatening neuromuscular emergency that can affect anyone, at anytime, and
 often requires prolonged hospitalization and intensive care¹
 - Following exposure to an infectious agent, activation of C1q and the classical complement system by antibodies that cross react with nerve components drives inflammation, motor neuron conduction block, and nerve damage²





biosciences

EQ-5D-5L, EuroQol 5-Dimension 5-Level; GBS, Guillain-Barré Syndrome; GBS-DS, GBS-disability score; IRR, infusion-related reaction; PGIC, Patient Global Impression of Change;

2 PROPRETARY AND CONFIDENTIAL rODS, Rasch-built Overall Disability Score; VAS, visual analogue scale.

Results: Consistently Better Outcomes in Tanruprubart 30mg/kg Arm vs. Placebo





PGI-C

rODS

Rapid decrease in perceived disability with improvement in PGIC observed as early as Week 1 (OR 2.5; p=0.0028) and continuing through Week 8 (OR 1.4; p=0.2917)

biosciences

Conclusions [Poster 338]



Participants who received tanruprubart 30 mg/kg were able to **rapidly gain independence** across a range of basic and instrumental ADLs compared to placebo



EQ-5D-5L data correlate with rODS data, demonstrating **significant and sustained improvements** across **all functional health** domains



These results underscore the potential of tanruprubart to improve both **functional outcomes** as well as **overall health-related quality of life**

